Loading patent…
AssigneeKyowa Hakko Kogyo Co., Ltd.
InventorsYoshiyuki Yonetani, Takeshi Takahashi, Yuko Kanda, Tamio Mizukami, Tatsuya Tamaoki, Shun-ichi Ikeda, Masanobu Takashima, Naoki Asanuma, Tadashi Inaba, Hiroshi Takeuchi, Hiroshi Kawamoto, Yoshihisa Tsukada, Masato Satomura, Hiroshi Kitaguchi
Estimating the term…
A medicament for treatment of cancer comprising a compound represented by the following general formula (I) or a physiologically acceptable salt thereof: Ar1—S—R1—S—Ar2 wherein R1 represents a nonmetal bridging group; Ar1 and Ar2 independently represent a group selected from the group consisting of an aryl group which has, on its ring, one to three hydroxyl groups optionally substituted with a monovalent group and said aryl group may have one to three substituents other than hydroxyl group on its ring; and a heteroaryl group which has, on its ring, one to three hydroxyl groups optionally substituted with a monovalent group, and said heteroaryl group may have one to three substituents other than hydroxyl group on its ring.
A medicament for treatment of cancer comprising a compound represented by the following general formula (I) or a physiologically acceptable salt thereof:
A compound represented by the general formula (XII) or a salt thereof:
The compound or the salt thereof, wherein R22 and R23 are the same divalent groups;
The compound or the salt thereof, wherein R22 and R23 are the same divalent groups;
The compound or the salt thereof, wherein R22—N(R24)—R23 is represented by R101A—R101BCO—R101C—R101D—R101C—COR101B—R101A wherein R101A represents a C1-4 lower alkylene group;
Dependencies are inferred from the claim text.